Use of a T cell interferon gamma release assay in the investigation for suspected active tuberculosis in a low prevalence area by Winqvist, Niclas et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Infectious Diseases
Open Access Research article
Use of a T cell interferon gamma release assay in the investigation 
for suspected active tuberculosis in a low prevalence area
Niclas Winqvist*1,2, Per Björkman1, Ann Norén1 and Håkan Miörner3
Address: 1Infectious Disease Research Unit, Department of Clinical Sciences, Lund University, Malmö University Hospital, Malmö, Sweden, 
2Regional department of Infectious Disease Control and prevention, Malmö, Sweden and 3Medical microbiology, Department of laboratory 
medicine, Lund University, Lund, Sweden
Email: Niclas Winqvist* - Niclas.Winqvist@skane.se; Per Björkman - Per.Bjorkman@med.lu.se; Ann Norén - Ann.Noren@skane.se; 
Håkan Miörner - Hakan.Miorner@skane.se
* Corresponding author    
Abstract
Background:  In settings with low background prevalence of tuberculosis (TB) infection,
interferon-g release assays (IGRA) could be useful for diagnosing active TB. This study aims to
evaluate the performance of QuantiFERON®-TB Gold (QFT-G) in the investigation for suspected
active TB, with particular attention to patients originating in high-incidence countries. Furthermore,
factors associated with QFT-G results in patients with active TB were assessed.
Methods: From patients investigated for clinically suspected active TB, blood was obtained for
QFT-G testing, in addition to routine investigations. Positive (PPV) and negative (NPV) predictive
values for QFT-G were calculated, comparing patients with confirmed TB and those with other final
diagnoses. QFT-G results in TB patients originating from countries with intermediate or high TB
incidence were compared with QFT-G results from a control group of recently arrived
asymptomatic immigrants from high-incidence countries. Factors associated with QFT-G outcome
in patients with confirmed TB were assessed.
Results: Among 141 patients, 41/70 (58.6%) with confirmed TB had a positive QFT-G test,
compared to 16/71 (22.6%) patients with other final diagnoses, resulting in overall PPV of 71.9%
and NPV of 67.6%. For patients with pulmonary disease, PPV and NPV were 61.1% and 67.7%,
respectively, and 90.5% and 66.7% for subjects with extrapulmonary manifestations. Comparing
patients from high-incidence countries with controls yielded a PPV for active TB of 76.7%, and a
NPV of 82.7%. Patients with confirmed TB and positive QFT-G results were characterized by a
lower median peripheral white blood cell count (5.9 × 109/L vs. 8.8 × 109/L; P < 0.001) and a higher
median body mass index (22.7 vs. 20.7; P = 0.043) as compared to QFT-G-negative TB patients.
Conclusion: The overall PPV and NPV of QFT-G for identifying active TB were unsatisfactory,
especially for pulmonary disease. Thus, the usefulness of QFT-G for this purpose is questionable.
However, a high PPV was observed for extrapulmonary TB and QFT-G might be considered in the
diagnostic process in this situation. The PPV and NPV for identifying active TB among persons
originating from regions with high-and intermediate TB incidence was similar to that observed in
subjects originating in the low-incidence region.
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Background
Even in low prevalence regions, TB is a common differen-
tial diagnosis in infectious disease practice, and different
manifestations of TB may be encountered in all medical
disciplines. Whereas most cases of pulmonary tuberculo-
sis can be easily identified by detection of bacteria in air-
way secretions, the diagnosis of extrapulmonary TB is
often difficult to establish. Recently, new diagnostic kits
for tuberculosis infection, known as interferon-gamma
release assays (IGRA:s), have become commercially avail-
able. T-SPOT®. TB (Oxford Immunotec Ltd.) is an assay
that enumerates TB specific T-lymphocytes by Elispot
technique [1], whereas QuantiFERON®-TB and QuantiF-
ERON®-TB Gold (QFT-G; Cellestis Ltd.), are based on
ELISA-techniques that measure g-interferon released by
TB specific T-lymphocytes [2]. Both of these tests appear
to have higher specificity than the tuberculin skin test
(TST) for TB infection [3-6], but the absence of a definite
method to diagnose latent TB infection makes direct com-
parison between diagnostic methods impossible. In low-
prevalence regions, TST is of limited value for detection of
TB infection, since a high proportion of reactive skin tests
have other aetiologies than TB [7], such as recent BCG vac-
cination or exposure to environmental mycobacteria. In
addition to low specificity, the use of TST as a screening
tool in patients with suspected active TB is hampered by
high rates of false negative reactions in patients with active
TB, especially in case of underlying immunodeficiency
[8,9]. In the near future IGRA:s may even replace TST as a
test for diagnosing latent TB. However, at present their
role in the diagnostic process for suspected active infec-
tion remains uncertain.
Like TST, IGRA:s cannot differentiate between active and
latent TB. A number of studies examining IGRA results in
peripheral blood from patients with active TB has been
published, and have found surprisingly low sensitivity
[10-13]. Thus, their role in diagnosing active TB remains
uncertain. However, promising results have recently been
published with IGRA testing performed on mononuclear
cells obtained from the site of infection e.g. from bron-
cho-alveolar lavage [14].
Sweden has a low incidence of TB (5.5 per 100 000 inhab-
itants in 2007) [15]. In this setting with a low background
prevalence of latent TB, IGRA tests could be useful in the
initial diagnostic process in patients with suspected TB
[16]. During the last decades, clusters of TB have been
observed in large urban centres [16,17]. Considering the
epidemiological situation in many industrialized coun-
tries with a disproportionate fraction of TB cases occurring
in immigrants from high-incidence countries, the ability
of new diagnostic methods to detect patients with active
or latent TB in immigrant populations is of great impor-
tance.
The principal objective of this study was to define the use-
fulness of QFT-G in the diagnostic procedure for sus-
pected active tuberculosis among patients in Southern
Sweden by calculating PPV and NPV for QFT-G. In order
to assess the performance among persons originating
from high-prevalence areas, a group of healthy recently
arrived immigrants from such countries were compared to
those in patients with similar origin. We also aimed to
identify factors associated with QFT-G results in patients
with confirmed active TB.
Methods
Study population
This study was conducted in Malmö and Lund in South-
ern Sweden (population ca 400 000). In this area, about
40 cases of TB are reported annually. Study subjects
belonged to two categories: case patients with suspected
tuberculosis, and healthy immigrants who had recently
arrived in Sweden from countries with a high prevalence
of TB.
Patients were recruited consecutively from the depart-
ments of infectious and pulmonary diseases in the univer-
sity hospitals in Malmö and Lund between September
2004 and February 2007. Inclusion criteria were: age over
15 years, written informed consent, and ongoing investi-
gation for symptoms or signs for which TB was considered
as a differential diagnosis. Medical investigation typically
included microbiological testing from affected organs,
radiological investigations and histopathological studies,
according to disease manifestations. Patients were
excluded if TB treatment had been initiated more than 1
week prior to study entry, or if TB investigations were
done as part of a routine diagnostic package with no defi-
nite clinical suspicion of TB (e.g. patients undergoing
bronchoscopy for investigation of pulmonary lesions, in
which TB cultures are routinely obtained). For patients
with suspected TB, an interview and record-based ques-
tionnaire covering general medical history, risk factors for
exposure to TB and details concerning ongoing disease
and results of medical investigations was completed by
either a physician or a specialized nurse. TST was recom-
mended, but not required, for study inclusion.
Since around 80 percent of all TB cases in the study area
occur among immigrants from countries with high or
intermediate TB incidence [18] we chose to compare
results in immigrant patients with active TB with those in
healthy subjects with similar geographical origin. A con-
trol group of recently (within 7 months) arrived immi-
grants, aged over 15 years and without significant medical
history, were recruited from a primary care centre per-
forming health examinations, which are offered to all
immigrants arriving in Sweden. Recruitment of immi-
grants was performed between March 2006 and Septem-BMC Infectious Diseases 2009, 9:105 http://www.biomedcentral.com/1471-2334/9/105
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ber 2006. These examinations include a general health
questionnaire, voluntary HIV test, chest X-ray and TST.
A TB case was defined as an individual with symptoms
and signs compatible with TB and isolation of, or detec-
tion of nucleic acid from, Mycobacterium tuberculosis com-
plex from a clinical specimen (microbiologically
confirmed TB), or as a patient with tuberculosis clinically
suspected by an expert physician, and responding to anti-
tuberculosis treatment[19].
QuantiFERON-TB® Gold test
Whole blood was collected in heparin-containing tubes
for the QuantiFERON®-TB Gold test (Cellestis Ltd, Victo-
ria, Australia). Samples were transported to the laboratory
within 4 hours and incubation with antigens was initiated
within 7 hours after collection. Antigens provided in the
QFT-G test kit were the 6 kDa early secreted antigenic tar-
get (ESAT-6) and culture filtrate protein 10 (CFP-10); in
addition to these, TB7.7 (kindly provided by Karin Weld-
ingh; Statens Serum Institut, Copenhagen, Denmark) and
purified protein derivative (PPD; Art. No 2390; Statens
Serum Institut) were used for incubation experiments.
After 16 – 24 hours of incubation at 37°C in 5% CO2,
supernatants were collected and frozen at -20°C until
analysis. Concentrations of interferon-gamma (INF-g) in
50 mL of plasma from whole-blood stimulated with the
antigens, mitogen (positive control) or saline (negative
control) were measured using the ELISA kit provided with
the QFT-G package. A positive result was defined as a con-
centration of INF-g of ³0.35 IU/mL after subtraction of
the INF-g concentration from the negative control in at
least 1 of the specific antigens ESAT-6, CFP-10 or TB7.7.
The INF-g concentration in the antigen stimulated wells
had to be at least half of the concentration of the negative
control for the result to be valid. If the mitogen response
minus the negative control was < 0.5 the result was
defined as indeterminate.
The results of the QFT-G tests were not available to the
physicians in charge of the patients, and thus did not
influence the diagnostic procedure.
Tuberculin skin test
TST was done by intradermal injection of 0.1 ml (2 TU)
PPD (RT23; Statens Serum Institut, Copenhagen, Den-
mark). Skin induration was measured after 72 hours and
was interpreted according to the recommendations by the
manufacturer. In most cases TST was done prior to QFT-G
or at the same time.
Statistical methods
Positive (PPV) and negative (NPV) predictive values of the
QFT-G test among patients were calculated using a final
TB diagnosis as true positive and other final diagnoses as
true negative outcome. To facilitate comparisons with
other studies, calculations of sensitivity and specificity for
the diagnosis of active TB were also performed. McNemar
test was used to test for overall accuracy. Patients with
indeterminate QFT-G results were excluded from the anal-
ysis.
Patients originating from high and intermediate preva-
lence regions were compared with healthy immigrant
controls to determine PPV and NPV for active TB of both
QFT-G and TST in the immigrant population. In patients
with confirmed TB, factors associated with positive or neg-
ative QFT-G result were first determined by univariate
regression analysis. In order to control for possible con-
founding factors, variables were then put into a multiple
regression model.
For dichotomous variables an odds ratio was calculated.
Differences in odds ratio with a p-value <.05 was consid-
ered significant. Odds ratios were defined as the exponent
of the estimated beta for dichotomous variables. When
comparing means for continuous variables the Student's t-
test was used for variables with normal distribution. For
other variables the Mann-Whitney's non-parametric test
was used.
The study procedure was approved by the ethical vetting
board, Lund University, Sweden.
Results
Patients with suspected tuberculosis
In 70 of 141 patients, the diagnosis of TB was established,
whereas 71 patients received another final diagnosis
(most frequent were bacterial pneumonia [17], cancer [5],
and other respiratory diseases [4]). Characteristics of the
patients are shown in Table 1. TB was bacteriologically
confirmed either by culture, microscopy or polymerase
chain reaction (PCR) in 61 patients (87%); in the remain-
ing 9 patients, diagnosis was based on clinical criteria,
supported by radiological and/or histopathological find-
ings, and response to anti-tuberculosis therapy.
Patients originating from countries with an estimated TB-
incidence of more than 20 new cases per 100 000 inhab-
itants according to the World Health Organization
(WHO)[20] were significantly more likely to get a TB diag-
nosis compared to those from low incidence countries
(52/75 vs. 18/66; P < 0.001). Patients with TB were also
younger than those with another final diagnosis (median
age 38 years vs. 58; P < 0.001). Other parameters analyzed
did not differ significantly between patients with con-
firmed TB and non-TB cases.
QuantiFERON-TB® Gold results in patients with suspected 
tuberculosis
Results of QFT-G for respective patient categories are pre-
sented in Table 2. Ten subjects had indeterminate QFT-GBMC Infectious Diseases 2009, 9:105 http://www.biomedcentral.com/1471-2334/9/105
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results; these patients did not differ significantly from
those with a positive or negative QFT-G result with regard
to any of the parameters tested.
For the whole group of patients, the PPV and NPV of QFT-
G was 71.9% and 67.6%, respectively. The sensitivity and
specificity for QFT-G was 63.1% and 75.8% respectively
(McNemar test for overall accuracy: P = 0.268).
Among 104 patients with pulmonary disease manifesta-
tions, QFT-G was positive in 22 of 44 TB-cases and in 14
out of 60 non-TB patients, (PPV 61.1%, NPV 67.7%; Table
2). In this subgroup the sensitivity was 52.4% and the spe-
cificity 75.0% (McNemar test: P = 0.392).
Thirty-seven patients had suspected extrapulmonary TB.
Out of these, 21 had a positive QFT-G test, 12 had a neg-
ative test and in 4 subjects the QFT-G result was indeter-
minate (Table 2). Two of the 21 QFT-G-positive subjects
with suspected extrapulmonary TB received a final diag-
nosis other than TB. The PPV and NPV of QFT-G in sub-
jects with suspected extrapulmonary TB was 90.5% and
66.7% and sensitivity and specificity was 82.6% and
80.0% respectively (McNemar test: P = 0.687).
In the subgroup of patients originating from countries
with high or intermediate TB incidence, PPV and NPV
were 78.6% and 46.7% respectively (pulmonary and
extrapulmonary disease manifestations combined).
Table 1: Characteristics of patients investigated for suspected active tuberculosis, and controls
Tuberculosis
n = 70
Other final diagnoses
n = 71
Controls
n = 98
Women (%) 40 (57.1) 35 (49.3) 35 (35.7)
Median age (years) 38 58 32
Median BMI 22 23
Origin from country with high or intermediate TB-incidence* (%) 52 (74.3) 23 (32.4) 98 (100)
Immune supression** (%) 19 (27.1) 28 (39.4) 0 (0.0)
Affected organ
Lung (%) 44 (62.9) 60 (84.5)
Pleura (%) 3 (4.3) 1 (1.4)
Mediastinal lymph node (%) 1 (1.4) 2 (2.8)
Peripheral lymph node (%) 10 (14.3) 1 (1.4)
Joint/skeleto-muscular (%) 3 (4.3) 3 (4.3)
Skin/soft tissue (%) 2 (2.8) 1 (1.4)
Gastrointestinal/abdominal (%) 4 (5.7) 0 (0.0)
Urogenital (%) 0 (0.0) 1 (1.4)
Multiple locations (%) 3 (4.3) 2 (2.8)
TB: Tuberculosis; BMI: Body Mass Index
* Defined as ³20 cases/100 000 inhabitants
** HIV-infection (n = 6), immunosuppressive treatment (n = 18), diabetes (n = 9), alcohol or drug abuse (n = 9), cancer (n = 4), Mb Down (n = 1)
Table 2: Positive and negative predictive values of QuantiFERON®-TB Gold results in patients with confirmed TB and patients with 
other final diagnoses.
Tuberculosis*
n = 70
Other final diagnosis*
n = 71
Positive predictive value Negative predictive value
All patients; n = 141
QFT-G positive 41 16
QFT-G negative 24 50 71.9% 67.6%
QFT-G indeterminate 5 5
Suspected pulmonary TB; n = 104
QFT-G positive 22 14
QFT-G negative 20 42 61.1% 67.7%
QFT-G indeterminate 2 4
Suspected extrapulmonary TB; n = 37
QFT-G positive 19 2
QFT-G negative 4 8 90.5% 66.7%
QFT-G indeterminate 3 1
QFT-G: QuantiFERON®-TB Gold; TST: Tuberculin skin test
* Bacteriological and/or clinical diagnosisBMC Infectious Diseases 2009, 9:105 http://www.biomedcentral.com/1471-2334/9/105
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Immigrants from high and intermediate prevalence 
countries – comparison of QFT-G results among patients 
with tuberculosis and healthy controls
The TB incidence in the country of origin was lower
among the 98 immigrant controls than for the 52 patients
who originated from high and intermediate prevalence
regions (mean 63 vs. 158 new cases/100 000 inhabitants;
P < 0.001). The mean age of the control subjects was lower
than that of the immigrant patients (31.8 years vs. 42.6; P
< 0.001) and the male/female ratio was higher (63/35 vs.
41/42). The most common countries of origin were Iraq
(58), the Palestine (11) and Somalia (7) for the immi-
grant controls, and Serbia (9), Somalia (9), Bosnia-Herze-
govina (8), Iraq (8) and Afghanistan (8) for the
immigrant patients.
Among the 52 immigrant patients with confirmed TB, 33
(63.5%) had positive QFT-G results. QFT-G results could
be determined in 96 of 98 controls. Among these, 10
(10.4%) had a positive result. In control subjects with TST
results, the induration was ³10 mm in 39 of 85 (45.9%)
persons.
When comparing subjects from high-prevalence coun-
tries, the PPV for a positive QFT-G in patients with active
TB was 76.7%, and the NPV was 82.7%. The correspond-
ing PPV and NPV for a TST with cut off of 10 mm was
44.3% and 93.9% respectively (Table 3). In terms of sen-
sitivity and specificity the results were for QFT-G 67.3%
and 89.6% respectively (McNemar test for overall accu-
racy: P = 0.327) and for TST 91.2% and 54.1% respectively
(McNemar test: P < 0.001).
Factors associated with QFT-G result in patients with 
active tuberculosis
To further explore factors that may influence the QFT-G
results in TB-patients, various parameters were tested. The
findings are divided with regard to the variable's quality
(dichotomous or scale) and are presented in Table 4 and
5. Positive QFT-G results were more common in patients
with extrapulmonary TB than in those with pulmonary
disease. The concentration of INF-g was also significantly
higher in patients with extrapulmonary symptoms com-
pared to patients with pulmonary symptoms (mean 11.3
IU/mL vs. 1.9 IU/mL; Student's t-test: P < 0.001). The dif-
ference between women and men was borderline signifi-
cant, with a higher likelihood of positive results in women
(OR 2.70; 95% CI: 0.96–7.62; P = 0.0504).
Mean score of body mass index (BMI; kg/m2) for QFT-G
positive TB patients was 22.7 compared to 20.7 for QFT-G
negative subjects (Student's t-test: P  = 0.043). Patients
with a positive QFT-G test had a significantly lower
peripheral white blood cell count (WBC) than QFT-G neg-
ative subjects (mean 5.9 vs. 8.8 × 109/L; Student's t-test: P
< 0.001). In patients with TST results, the skin induration
was significantly larger in QFT-G positive individuals
(mean 23 mm and 15 mm respectively; Student's t-test: P
= 0.025).
In order to account for confounding factors, parameters
that may influence the QFT-G result were entered into a
logistic regression model (Table 6). After controlling for
sex and a diagnosis of extrapulmonary TB, the only signif-
icant difference was a lower WBC in QFT-G positive indi-
viduals.
Antigens for incubation experiments
The antigens added for incubation experiments, TB7.7
and PPD, did not show a significant effect on the results.
Six positive QFT-G tests based on TB7.7 only were noted,
2 each in the TB patient group, the non-TB patient group
and the group of healthy immigrants. QFT-PPD was used
for experiments only and did not give rise to positive QFT-
G results alone. The correlation between QFT-PPD and
TST was 0.232 (Pearson's correlation test; P = 0.075). In
TB patients there was a significant, negative correlation
between WBC and QFT-PPD (-3.178; Pearson's correla-
tion test; P = 0.003).
Table 3: Comparison of QFT-G and TST results in TB patients and controls with origin from country with intermediate or high TB 
incidence (n = 150).
TB-patients*
n = 52
Controls
n = 98
Positive predictive value Negative predictive value
QFT-G positive 33 10
QFT-G negative 16 86 76.7% 84.3%
QFT-G indeterminate 3 2
TST ³ 10 mm 31 39
TST <10 mm 3 46 44.3% 93.9%
TST not performed 18 13
QFT-G: QuantiFERON®-TB Gold; TST: Tuberculin skin test
* Bacteriological and/or clinical diagnosisBMC Infectious Diseases 2009, 9:105 http://www.biomedcentral.com/1471-2334/9/105
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Discussion
Correct diagnosis of tuberculosis remains a challenge in
clinical practice, especially for extrapulmonary disease
manifestations for which invasive procedures are required
to detect mycobacteria in affected tissues. In this study,
performed among patients investigated for suspected TB
in a low-prevalence region, the overall usefulness of QFT-
G as part of the initial diagnostic procedure was limited,
with a low negative predictive value for identifying active
TB. Interestingly, we observed that a negative QFT-G reac-
tion was more common in pulmonary TB than among
patients with extrapulmonary disease manifestations.
Among patients with extrapulmonary disease, QFT-G per-
formed much better. Most patients with extrapulmonary
TB in our material had isolated peripheral lymphadenitis.
Lymph node biopsies were obtained in several of these
patients, and showed pronounced granulomatous inflam-
matory reaction; in addition, the mycobacterial load was
low, since bacterial growth was only detected from biop-
sies and not in fine-needle aspirates. Such a presentation
is common in peripheral tuberculous lymphadenitis in
HIV-negative patients, and is related to a strong immune
response [21], further supported by the finding of high
IFN-g secretion in such patients[22,23].
Our results on the PPV and NPV of IGRA in active TB are
in agreement with those reported by others [10,13,24,25].
The limited sensitivity of IGRA tests in active TB could be
related to the secretion of IFN-g suppressive factors in
active TB [26], or to the immunological capacity of the
host to contain mycobacterial replication [23]. IFN-g
secretion has been shown to be inversely correlated to dis-
ease severity in patients with TB [23,27,28]. Lower rates of
IFN-g secretion and higher frequencies of indeterminate
IGRA results have also been observed in HIV-infected sub-
jects [29-31]. We did not find any correlation with QFT-G
results and the presence of immunosuppression in our
patients; however, the proportion of HIV-infected subjects
Table 4: Dichotomous variables; association with QFT-G results in tuberculosis patients
QFT positive QFT negative Odds ratio 95% CI interval p-value
Male 14 14 2.70 0.96 – 7.62 0.0504
Female 27 10
Origin from high or intermediate TB incidence country* 33 16 2.04 0.63 – 6.66 0.1710
Origin from low incidence country 8 8
Born abroad and lived <5 years in Sweden 14 5 1.95 0.61 – 6.96 0.1970
Born in, or lived >5 years in, Sweden 27 19
Extra pulmonary tuberculosis 19 4 4.31 1.25 – 14.87 0.0142
Pulmonary tuberculosis 22 20
Sputum smear negative** 9 6 1.62 0.38 – 7.15 0.4666
Sputum smear positive 13 14
Immunosuppressed patients *** 9 8 1.76 0.55 – 5.58 0.2357
Immune-competent patients 32 16
TST ³ 10 mm 27 9 3.00 0.37 – 24.50 0.3000
TST < 10 mm 2 2
QFT: QuantiFERON®-TB Gold; CI: Confidence Interval; BMI: Body Mass Index (kg/m2); TST: Tuberculin skin test
5 patients with indeterminate results excluded
* High or moderate TB-incidence is defined as ³20 cases/100 000 population
** For pulmonary TB only (result missing in 2 patients)
*** Immune suppression defined as HIV-infection, ongoing immunosuppressive treatment, cancer, diabetes, alcohol or drug abuse
Table 5: Means of scale variables and their association with QFT result in TB patients
Number of observations QFT positive QFT negative 95% CI of difference t-test p-value
Age (years) 65 42 44 -12.4–7.9 -0.45 0.657
TB incidence of native country 
(new cases/100 000 pop.)
65 133 87 -17.7–110.0 1.45 0.157
Body Mass Index (BMI) 58 22.7 20.7 0.1–4.0 2.08 0.043*
Hemoglobin (Hb; g/L) 59 125 121 -0.7–14.3 1.01 0.315
ESR (mm) 41 45 56 -31.5–9.2 -1.12 0.272
C-reactive protein (CRP; mg/L) 59 42 79 -76.9–2.4 -1.91 0.065
Total leukocyte count (cells × 109/L) 60 5.9 8.8 -4.3–-1.4 -4.02 <0.001*
TST (mm) 40 23 15 1.2–15.4 2.40 0.025*
* Significant difference of meansBMC Infectious Diseases 2009, 9:105 http://www.biomedcentral.com/1471-2334/9/105
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in our material was rather low. For T-SPOT®. TB, indeter-
minate results have been associated with delayed han-
dling times [32], whereas an evaluation of cytokine
techniques under different circumstances found that
ELISA performance was not much affected by handling
conditions [33]. The rate of indeterminate results was
7.1% (10/141) in this study, which is at the same level as
reported in other studies on patients with suspected clini-
cally active TB disease [34]. The rate of false negative was
34% in this study (24/70). There are large variations in the
literature but several other studies have reported a similar
low sensitivity in patients with active tuberculosis
[10,13,35,36]. In our study, all samples were sent to the
laboratory and processed within 7 hours; thus, it is
unlikely that technical problems explain the high fre-
quency of negative and indeterminate results in patients
with confirmed active TB.
It has been suggested to lower the cut-off limits for the
IGRA tests in low incidence settings in order to improve
sensitivity[37]. Recalculating PPV and NPV in our mate-
rial using the cut-off limits 0.20 IU/mL and 0.10 IU/mL
reduced PPV for patients with pulmonary and extrapul-
monary TB respectively. Only the lowest cut-off limit
raised the NPV slightly (data not shown). Hence, lowering
cut-off limits for the QFT-G would not benefit the test's
performance in our setting.
The magnitude and characteristics of immune response
are important factors for the pathogenesis and disease
manifestations in tuberculosis, and they are likely to be
associated with the rate of IFN-g secretion. A parallel may
be drawn to leprosy, another mycobacterial infection in
which the immune response is critical for disease presen-
tation. In an Indian study, significantly higher IFN-g
secretion was detected in patients with tuberculoid vari-
ants of leprosy, as opposed to lepromatous forms (in
which the Th-1 response is weak) [38]. The association
between WBC in peripheral blood and QFT-G outcome in
our TB patients could be a reflection of the same phenom-
enon, and are in agreement with findings reported by
Shang and co-workers, showing enhanced peripheral
blood leukocytosis in mice with targeted mutation of
chemokine receptor 1 and reduced IFN-g secretion [39].
The lower BMI in QFT-G negative TB-patients is also likely
to be related to a reduced capacity for INF-g secretion in
patients with advanced disease.
When assessing the usefulness of IGRA testing for detect-
ing active TB, the immunological profile of the studied
patients should thus be taken into account. Our results
may not be applicable for HIV-positive patients. Further-
more, several IGRA techniques have been developed, and
in a meta-analysis of commercially available IGRA:s dif-
ferences with regard to sensitivity and applicability have
been found [6,16]. We used an extended, in-house variant
of QuantiFERON®-TB Gold, with the addition of another
MTB specific antigen (TB7.7) apart from those included in
the commercial kit. However, the inclusion of this antigen
did not appear to affect test outcome. In this study, we
have not compared the two different IGRA test methods.
Although comparisons between QFT-G and T-SPOT®. TB
suggest that the latter may be more sensitive for diagnos-
ing latent TB, the significance of this difference in clinical
practice is not clear. Furthermore, QFT has the advantage
of being easier and less expensive to perform than T-
SPOT®. TB testing. Both IGRA test methods have superior
specificity for TB compared to TST, but sensitivity is prob-
ably lower (depending on the TST cut-off chosen to define
TB infection). However, in analogy with QFT-G, false neg-
ative TST reactions are common in severe forms of TB
[40].
An important finding from our study is that QFT-G had
similar positive and negative predictive values for active
TB among native Swedes and immigrants from high-prev-
Table 6: Multiple logistic regression analysis of factors potentially associated with QFT-results in TB-patients (after controlling for sex 
and extrapulmonary TB)
Factor Number of observations Est. beta-coefficient OR* 95% CI p-value
Bacteriologically verified diagnosis 65 -0.022 0.98 0.20–4.78 0.977
TST cut off 10 mm 40 -0.666 0.51 0.21–1.28 0.153
TST cut off 15 mm 40 1.384 3.99 0.72–22.15 0.114
Immune suppression** 65 -0.680 0.51 0.15–1.76 0.284
TB incidence of native country (new cases/100 000 pop.) 65 0.003 0.200
Body Mass Index (BMI) 58 0.146 0.110
Hemoglobin (mg/L) 59 0.022 0.181
Erythrocyte Sedimentation Rate (mm) 41 -0.005 0.995
C-reactive protein (CRP;mg/L) 59 -0.007 0.124
White blood cell count (WBC; × 109/L) 60 -0.568 <0.001
*Odds ratios (defined as the exponent of the estimated beta) are not shown for TB incidence of native country, BMI, Hb, ESR, CRP and WBC since 
these variables are not dichotomous.
** Immune suppression defined as HIV-infection, ongoing immunosuppressive treatment, cancer, diabetes, alcohol or drug abuseBMC Infectious Diseases 2009, 9:105 http://www.biomedcentral.com/1471-2334/9/105
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alence countries – a group that presently constitutes the
majority of TB patients in Sweden as well as in most other
European countries. This is somewhat surprising in view
of the limited sensitivity of QFT-G for active TB, and the
presumed high prevalence of latent TB among the healthy
immigrant controls (TST ³ 10 mm in 39/85, 46%). With
regard to the fact that the incidence of TB in the countries
of origin among immigrant patients was higher than in
controls, it may be anticipated that the exposure to TB was
different between these groups. Still, this observation
raises further questions regarding the significance of QFT-
G and TST for identification of persons infected with M.
tuberculosis.
Conclusion
The overall usefulness of QFT-G for identifying active TB
was limited among patients investigated for suspected TB
in a typical setting in a North-European low-prevalence
region. Poor performance was more common in patients
with pulmonary disease, whereas the PPV for QFT-G was
satisfactory among patients with extrapulmonary disease
manifestations. Since TB is more difficult to diagnose in
such cases, we suggest that it may be reasonable to con-
sider QFT-G for screening patients with suspected
extrapulmonary TB. Furthermore, the PPV and NPV of
QFT-G for detection of actitve TB among immigrants from
high and intermediate prevalence regions seem to be sim-
ilar to that observed in non-immigrants.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
NW, PB and HM were responsible for planning the study,
analyzing the results and drafting the manuscript. HM
designed the antigen panel used for QFT-G testing. NW,
AN and PB collected the study material and coordinated
the study. All authors have read and approved the manu-
script.
Acknowledgements
Skane county council's research and development foundation and the 
Swedish Heart-Lung Foundation supported the study financially. We would 
like to acknowledge all doctors and nurses at the participating departments 
of infectious and pulmonary diseases in the university hospitals in Malmö 
and Lund for their involvement in patient enrollment and specimen collec-
tion. Special thanks also to Arne Forsgren, Department of laboratory med-
icine, Malmö, Lund University, for help in planning the study, Annica 
Andreasson at Clinical microbiology and immunology, Lund university hos-
pital, Lund for performing the QFT-G test and Håkan Lövkvist at Compe-
tence Centre for Clinical Research, Lund for statistical assistance.
References
1. Lalvani A, Pathan AA, Durkan H, Wilkinson KA, Whelan A, Deeks JJ,
Reece WH, Latif M, Pasvol G, Hill AV: Enhanced contact tracing
and spatial tracking of Mycobacterium tuberculosis infection
by enumeration of antigen-specific T cells.  Lancet 2001,
357(9273):2017-2021.
2. Ravn P, Munk ME, Andersen AB, Lundgren B, Nielsen LN, Lillebaek T,
Soerensen IJ, Andersen P, Weldingh K: Reactivation of tuberculo-
sis during immunosuppressive treatment in a patient with a
positive QuantiFERON-RD1 test.  Scandinavian journal of infec-
tious diseases 2004, 36(6–7):499-501.
3. Fietta A, Meloni F, Cascina A, Morosini M, Marena C, Troupioti P,
Mangiarotti P, Casali L: Comparison of a whole-blood inter-
feron-gamma assay and tuberculin skin testing in patients
with active tuberculosis and individuals at high or low risk of
Mycobacterium tuberculosis infection.  American journal of infec-
tion control 2003, 31(6):347-353.
4. Meier T, Eulenbruch HP, Wrighton-Smith P, Enders G, Regnath T:
Sensitivity of a new commercial enzyme-linked immunospot
assay (T SPOT-TB) for diagnosis of tuberculosis in clinical
practice.  Eur J Clin Microbiol Infect Dis 2005, 24(8):529-536.
5. Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K,
Shigeto E, Harada N, Mitarai S, Okada M, et al.: Specific detection
of tuberculosis infection: an interferon-gamma-based assay
using new antigens.  American journal of respiratory and critical care
medicine 2004, 170(1):59-64.
6. Pai M, Zwerling A, Menzies D: Systematic review: T-cell-based
assays for the diagnosis of latent tuberculosis infection: an
update.  Annals of internal medicine 2008, 149(3):177-184.
7. Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM: A
meta-analysis of the effect of Bacille Calmette Guerin vacci-
nation on tuberculin skin test measurements.  Thorax 2002,
57(9):804-809.
8. Bloom BR, Small PM: The evolving relation between humans
and Mycobacterium tuberculosis.  The New England journal of
medicine 1998, 338(10):677-678.
9. Boussiotis VA, Tsai EY, Yunis EJ, Thim S, Delgado JC, Dascher CC,
Berezovskaya A, Rousset D, Reynes JM, Goldfeld AE: IL-10-produc-
ing T cells suppress immune responses in anergic tuberculo-
sis patients.  The Journal of clinical investigation 2000,
105(9):1317-1325.
10. Ferrara G, Losi M, D'Amico R, Roversi P, Piro R, Meacci M, Meccugni
B, Dori IM, Andreani A, Bergamini BM, et al.: Use in routine clinical
practice of two commercial blood tests for diagnosis of infec-
tion with Mycobacterium tuberculosis: a prospective study.
Lancet 2006, 367(9519):1328-1334.
11. Goletti D, Carrara S, Vincenti D, Saltini C, Rizzi EB, Schinina V,
Ippolito G, Amicosante M, Girardi E: Accuracy of an immune
diagnostic assay based on RD1 selected epitopes for active
tuberculosis in a clinical setting: a pilot study.  Clin Microbiol
Infect 2006, 12(6):544-550.
12. Lee JY, Choi HJ, Park IN, Hong SB, Oh YM, Lim CM, Lee SD, Koh Y,
Kim WS, Kim DS, et al.: Comparison of two commercial inter-
feron-gamma assays for diagnosing Mycobacterium tubercu-
losis infection.  Eur Respir J 2006, 28(1):24-30.
13. Mazurek GH, Weis SE, Moonan PK, Daley CL, Bernardo J, Lardizabal
AA, Reves RR, Toney SR, Daniels LJ, LoBue PA: Prospective com-
parison of the tuberculin skin test and 2 whole-blood inter-
feron-gamma release assays in persons with suspected
tuberculosis.  Clin Infect Dis 2007, 45(7):837-845.
14. Jafari C, Lange C: Suttons's Law: Local Immunodiagnosis of
Tuberculosis.  Infection 2008, 36(6):510-514.
15. Tuberculosis in Sweden   [http://www.smittskyddsinstitutet.se/sta
tistik/tuberkulos]
16. Menzies D, Pai M, Comstock G: Meta-analysis: new tests for the
diagnosis of latent tuberculosis infection: areas of uncer-
tainty and recommendations for research.  Annals of internal
medicine 2007, 146(5):340-354.
17. Kan B, Berggren I, Ghebremichael S, Bennet R, Bruchfeld J, Chryssan-
thou E, Kallenius G, Petersson R, Petrini B, Romanus V, et al.: Exten-
sive transmission of an isoniazid-resistant strain of
Mycobacterium tuberculosis in Sweden.  Int J Tuberc Lung Dis
2008, 12(2):199-204.
18. Winqvist N, Andersen PH, Lillebaek T, Bjorkman P, Miorner H:
Demographics of tuberculosis in an emerging EU region in
southern Scandinavia.  Scandinavian journal of infectious diseases
2006, 38(11–12):1033-1039.
19. Welfare TNBoHa: Case definitions on report in accordance
with the Swedish Disease Control and Prevention Act.  Wel-
fare TNBoHa: The National Board of Health and Welfare; 2008. 
20. Global tuberculosis control – surveillance, planning, financ-
ing   [http://www.who.int/tb/publications/global_report/2008/en/]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Infectious Diseases 2009, 9:105 http://www.biomedcentral.com/1471-2334/9/105
Page 9 of 9
(page number not for citation purposes)
21. Polesky A, Grove W, Bhatia G: Peripheral tuberculous lymphad-
enitis: epidemiology, diagnosis, treatment, and outcome.
Medicine 2005, 84(6):350-362.
22. Habte A, Geletu M, Olobo JO, Kidane D, Negesse Y, Yassin MA, Kifle
B, Abate G, Harboe M, Aseff A: T cell mediated immune
responses in patients with tuberculous lymphadenitis from
Butajira, southern Ethiopia.  Ethiopian medical journal 2004,
42(Suppl 1):29-35.
23. Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN,
Pasvol G, Hill AV, Lalvani A: Direct ex vivo analysis of antigen-
specific IFN-gamma-secreting CD4 T cells in Mycobacte-
rium tuberculosis-infected individuals: associations with clin-
ical disease state and effect of treatment.  J Immunol 2001,
167(9):5217-5225.
24. Dewan PK, Grinsdale J, Kawamura LM: Low sensitivity of a whole-
blood interferon-gamma release assay for detection of
active tuberculosis.  Clin Infect Dis 2007, 44(1):69-73.
25. Pai M, Joshi R, Bandyopadhyay M, Narang P, Dogra S, Taksande B,
Kalantri S: Sensitivity of a whole-blood interferon-gamma
assay among patients with pulmonary tuberculosis and vari-
ations in T-cell responses during anti-tuberculosis treat-
ment.  Infection 2007, 35(2):98-103.
26. Pai RK, Convery M, Hamilton TA, Boom WH, Harding CV: Inhibi-
tion of IFN-gamma-induced class II transactivator expres-
sion by a 19-kDa lipoprotein from Mycobacterium
tuberculosis: a potential mechanism for immune evasion.  J
Immunol 2003, 171(1):175-184.
27. Goletti D, Butera O, Bizzoni F, Casetti R, Girardi E, Poccia F: Region
of difference 1 antigen-specific CD4+ memory T cells corre-
late with a favorable outcome of tuberculosis.  The Journal of
infectious diseases 2006, 194(7):984-992.
28. Sodhi A, Gong J, Silva C, Qian D, Barnes PF: Clinical correlates of
interferon gamma production in patients with tuberculosis.
Clin Infect Dis 1997, 25(3):617-620.
29. Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P:
Latent tuberculosis in HIV positive, diagnosed by the M.
tuberculosis specific interferon-gamma test.  Respiratory
research 2006, 7:56.
30. Luetkemeyer AF, Charlebois ED, Flores LL, Bangsberg DR, Deeks SG,
Martin JN, Havlir DV: Comparison of an interferon-gamma
release assay with tuberculin skin testing in HIV-infected
individuals.  American journal of respiratory and critical care medicine
2007, 175(7):737-742.
31. Stephan C, Wolf T, Goetsch U, Bellinger O, Nisius G, Oremek G,
Rakus Z, Gottschalk R, Stark S, Brodt HR, et al.: Comparing Quan-
tiFERON-tuberculosis gold, T-SPOT tuberculosis and tuber-
culin skin test in HIV-infected individuals from a low
prevalence tuberculosis country.  AIDS (London, England) 2008,
22(18):2471-2479.
32. Beffa P, Zellweger A, Janssens JP, Wrighton-Smith P, Zellweger JP:
Indeterminate test results of T-SPOT.TB performed under
routine field conditions.  Eur Respir J 2008, 31(4):842-846.
33. Doherty TM, Demissie A, Menzies D, Andersen P, Rook G, Zumla A:
Effect of sample handling on analysis of cytokine responses
to Mycobacterium tuberculosis in clinical samples using
ELISA, ELISPOT and quantitative PCR.  J Immunol Methods
2005, 298(1–2):129-141.
34. Kobashi Y, Sugiu T, Shimizu H, Ohue Y, Mouri K, Obase Y, Miyashita
N, Oka M: Clinical evaluation of the T-SPOT.TB test for
patients with indeterminate results on the QuantiFERON
TB-2G test.  Intern Med 2009, 48(3):137-142.
35. Adetifa IM, Lugos MD, Hammond A, Jeffries D, Donkor S, Adegbola
RA, Hill PC: Comparison of two interferon gamma release
assays in the diagnosis of Mycobacterium tuberculosis infec-
tion and disease in The Gambia.  BMC infectious diseases 2007,
7:122.
36. Tsiouris SJ, Coetzee D, Toro PL, Austin J, Stein Z, El-Sadr W: Sensi-
tivity analysis and potential uses of a novel gamma interferon
release assay for diagnosis of tuberculosis.  Journal of clinical
microbiology 2006, 44(8):2844-2850.
37. Soysal A, Torun T, Efe S, Gencer H, Tahaoglu K, Bakir M: Evaluation
of cut-off values of interferon-gamma-based assays in the
diagnosis of M. tuberculosis infection.  Int J Tuberc Lung Dis 2008,
12(1):50-56.
38. Belgaumkar VA, Gokhale NR, Mahajan PM, Bharadwaj R, Pandit DP,
Deshpande S: Circulating cytokine profiles in leprosy patients.
Leprosy review 2007, 78(3):223-230.
39. Shang X, Qiu B, Frait KA, Hu JS, Sonstein J, Curtis JL, Lu B, Gerard C,
Chensue SW: Chemokine receptor 1 knockout abrogates nat-
ural killer cell recruitment and impairs type-1 cytokines in
lymphoid tissue during pulmonary granuloma formation.
The American journal of pathology 2000, 157(6):2055-2063.
40. Boras Z, Juretic A, Gagro A, Pavelic L: Cytokine profile of t lym-
phocytes from peripheral blood and bronchoalveolar lavage
fluid in patients with active pulmonary tuberculosis.  Scand J
Immunol 2007, 65(3):257-264.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/9/105/pre
pub